Latest news
Loading news…
Mabylon
ActiveOperating status — whether the company still runs independently. “Closed” usually means it was acquired, merged, or shut down.🔥 MediumHeat score — how much recent activity & attention the company has (web traffic, news, hiring).📈 Low growthGrowth score — momentum trend across web traffic, headcount and other growth signals. Schlieren, Zurich, Switzerland Founded 2015 11-50 employees For Profit
Mabylon develops novel antibody therapeutics in immunology & inflammation (I&I) and neurological disorders.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
0
Monthly Visits
Available in Pro Contacts
3
Patents
11
2 trademarks
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
IPO & Stock
- IPO status
- Private
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Technology & IP
- Active technologies
- 6
- Patents granted
- 11
- Trademarks
- 2
- Top patent class
- Medical Or Veterinary Science; Hygiene
- IT spend
- $124K
Company Info
- Founded
- 2015
- Employees
- 11-50
- Operating status
- Active
- Company type
- For Profit
- Org types
- company
- News articles
- 38
- HQ
- Schlieren, Zurich, Switzerland
- Region
- Europe, Middle East, and Africa (EMEA)
Signals & Scores
- Heat score
- Medium
- Growth score
- Low
- Trend (7d)
- -0.6
- Trend (30d)
- -2.7
- Trend (90d)
- -2.7
- Last leadership hire
- Aug 12, 2025
Key People at Mabylon
CEO & Director
Chairman of the Board
3
professional contacts at Mabylon
Contact execs at Mabylon →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to Mabylon
Loading news…
FAQs about Mabylon
People who checked this page also checked these
Browse the full Acquirezy directory.